Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy ... FDA earlier this year for all HER2-positive solid tumours, regardless of their location ...

2024 saw the first FDA approval of a cancer cell therapy that tackles solid tumours – Adaptimmune’s Tecelra (afamitresgene autoleucel) was approved in August to treat certain forms of synovial ...

AstraZeneca (NASDAQ:AZN) stock received a positive assessment from UBS, as analyst Matthew Weston upgraded the pharmaceutical giant's rating from Neutral to Buy. The upgrade was accompanied by a ...

UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

In oncology, immunotherapy stands as a transformative approach for treating solid tumors, notably through pioneering treatments like immune checkpoint ...